9 results about "Chlamydia trachomatis" patented technology

The invention relates to the technical field of molecular biology, and discloses an LAMP (loop-mediated isothermal amplification) primer group and a kit for detecting three items (Uu, CT and NG) of venereal diseases. The LAMP primer group disclosed by the invention comprises a first primer group for targeting a ureaplasma urealyticum UreB gene, a second primer group for targeting a chlamydia trachomatis gyrA gene and a third primer group for targeting a gonococcus glnA gene. The LAMP primer group provided by the invention has good thermal stability, is suitable for an LAMP amplification detection system at a high temperature of 70 DEG C, reduces non-specific binding, and has good detection sensitivity and specificity. The LAMP primer group and the kit provided by the invention provide an innovative solution for accurate diagnosis of sexually transmitted diseases.

The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.

The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.

The present application discloses a Pickering emulsion, its preparation method and application. The Pickering emulsion comprises an oil-in-water emulsion composed of graphene oxide quantum dots, an oil phase and an aqueous phase. The preparation method comprises the following steps: mixing a graphene oxide quantum dot solution, an oil phase and water to obtain a mixed solution, and emulsifying the mixed solution under ultrasonic conditions to obtain the Pickering emulsion. The Pickering emulsion uses graphene oxide quantum dots as an emulsifier. Due to the high surface area, biodegradability and biocompatibility of the graphene oxide quantum dots, the Pickering emulsion shows a high immune enhancement efficiency, can slowly release antigens in vivo and in vitro, has biocompatibility, and does not cause damage to the heart, liver and kidney functions of mice. It can be used as a candidate adjuvant with good immune enhancement and biocompatibility. The preparation method of the Pickering emulsion in the present invention is simple and easy to implement, and has low cost. The present invention also discloses the application of the above Pickering emulsion as an adjuvant for a Chlamydia trachomatis vaccine.

The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.

The application belongs to the technical field of biological detection and identification, and discloses a fluorescence PCR probe method detection kit for chameesiphanes grayanus, which comprises a pair of specific fluorescence primers CADQF and CADQR, a probe CADQP, a real-time fluorescence reaction mixture of 2xPremix Ex TaqTM PCR and ROXII, a positive control, a negative control and nuclease-free water; the sequence of the specific fluorescence primer CADQF is SEQ ID NO:1; and the sequence of the specific fluorescence primer CADQR is SEQ ID NO:2. The fluorescence PCR probe method detection kit can quickly and efficiently determine whether the sample to be tested is chameesiphanes grayanus, and can determine the type and content of raw materials in products that cannot be determined from morphology or use chameesiphanes grayanus as raw materials through the fluorescence PCR probe method, thereby providing a more convenient and efficient method for commodity quality and marine sample ecology.

The present disclosure relates to compounds and pharmaceutical compositions comprising same for the treatment, amelioration, and / or prevention of disease. In some embodiments, the disease is a bacterial infection. In some embodiments, the infection is caused by Acinetobacter spp., Clostridium spp., Enterococcus spp., Hemophilus spp., Legionella spp., Mycobacterium spp. (tuberculous and nontuberculous mycobacteria), Neisseria spp., Staphylococcus spp., Streptococcus spp., Listeria monocytogenes, Moraxella catarrhalis, Bacillus spp., Bacteroides spp., or any of the following: spp., Gardnerella vaginalis, Lactobacillus spp., Mobiluncus spp., Helicobacter pylori, Campylobacter jejuni, Chlamydia trachomatis, and / or Toxoplasma gondii. Preferably, the bacterial infection is caused by a bacterium belonging to the genus Staphylococcus aureus (S. aureus), A. baumannii (A. baumannii), E. faecium (E. faecalis), Staphylococcus epidermidis (S. epidermidis), Streptococcus pneumoniae (S. pneumoniae), Group A hemolytic streptococcus (S. pyogenes), Haemophilus influenzae (H. influenzae), M. abscessus (M. abscessus), M. tuberculosis (M. tuberculosis) and / or M. smegmatis (M.smegmatis), even more preferably the bacterial infection is caused by one or more bacteria belonging to the genus Acinetobacter, even more preferably by A. baumannii, even more preferably by A. baumannii having one or more resistance mechanisms to rifamycins, such as rifabutin and / or rifampicin.

The invention discloses a cervical cancer plasma circulating microbial marker combination, a reagent, a kit, a risk assessment model and application thereof, and belongs to the cross technical field of liquid biopsy and microbiomics. The cervical cancer plasma circulating microbial marker combination disclosed by the invention is prepared from prevotella, stenosiella, chlamydia trachomatis, peptostreptococcus, fusobacterium, campylobacter and haemophilus. Cervical cancer patients and healthy people are verified by using the cervical cancer plasma circulating microbial marker combination disclosed by the invention, the AUC value is 0.939, the sensitivity is 81.58%, the specificity is 90.00%, the accuracy is 85.29%, the positive predictive value is 91.18%, and the negative predictive value is 79.41%, so that the cervical cancer plasma circulating microbial marker combination disclosed by the invention can be used for effectively distinguishing the cervical cancer patients from the healthy people; the method is suitable for early screening of cervical cancer and has remarkable clinical screening application value.

The application discloses a cervical cancer plasma circulating microbial marker combination, a reagent, a kit, a risk assessment model and application thereof, and belongs to the technical field of liquid biopsy and microbiome. The cervical cancer plasma circulating microbial marker combination comprises Prevotella, Sneathia, Chlamydia trachomatis, Peptostreptococcus, Fusobacterium, Campylobacter and Haemophilus. The cervical cancer plasma circulating microbial marker combination is used for verifying cervical cancer patients and healthy people, and the AUC value is 0.939, the sensitivity is 81.58%, the specificity is 90.00%, the accuracy is 85.29%, the positive predictive value is 91.18%, and the negative predictive value is 79.41%, which indicates that the cervical cancer plasma circulating microbial marker combination can effectively distinguish cervical cancer patients from healthy people, is suitable for early screening of cervical cancer, and has significant clinical screening application value.